Business Context and Reporting Period
This Form 8-K reports on the results of the 2023 Annual Meeting of Stockholders for Rocket Pharmaceuticals, Inc. (RCKT), held on June 22, 2023. The company is incorporated in Delaware and its common stock trades on The Nasdaq Global Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
Stockholders representing approximately 89.14% of eligible shares (71,724,582 shares) participated in the meeting. Three proposals were voted upon:
- Proposal One (Election of Directors): All nine nominees were approved. Notably, Naveen Yalamanchi, M.D., received the highest number of votes withheld (20,168,849) compared to other nominees, though he was still elected.
- Proposal Two (Ratification of Accounting Firm): Stockholders ratified the appointment of EisnerAmper LLP for the fiscal year ending December 31, 2023, with 70,820,279 votes for and 901,600 votes against.
- Proposal Three (Say-on-Pay): The non-binding advisory vote on executive compensation was approved with 53,821,833 votes for and 10,527,507 votes against.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, or contingencies. The document is limited to the disclosure of voting results.
Investor Verification Checklist
- Verify the specific reasons for the significant number of votes withheld for director nominee Naveen Yalamanchi, M.D., by reviewing the full proxy statement.
- Confirm the total number of outstanding shares to validate the 89.14% participation rate.
- Review the separate proxy statement for detailed executive compensation data referenced in Proposal Three.
- Check subsequent filings (10-Q or 10-K) for the financial metrics absent in this 8-K.